monitoring infectious diseases
Given the destructive capabilities of infectious diseases and their ability to spread, early and accurate diagnosis is crucial, while monitoring blood levels of infectious agents like bloodbourne viruses is crucial to assess effectiveness of antiviral treatment.
As the world leader in in-vitro diagnostics, Roche offers the widest range of tests based on real-time polymerase chain reaction (RT-PCR) technology for detecting and monitoring infectious diseases. These are based on our deep insights into the mechanisms of infectious diseases and our expertise in molecular diagnostics.
For both hepatitis B and C, the concentration of hepatitis B virus (HBV) and hepatitis C virus (HCV), respectively, is an indication how a patient responds to antiviral treatment.
Roche’s COBAS® AmpliPrep/COBAS® TaqMan® HBV v2.0 and COBAS® AmpliPrep/COBAS® TaqMan® HCV Test detect and quantifiy the viruses’ genetic material in serum and plasma samples with much better sensitivty and accuracy than conventional methods.
Another test in the same product range enables the rapid, reliable and routine detection and monitoring of HIV-1. The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 targets two highly conserved regions of the HIV-1 genome to increase the probability of detection.
Immunocompromised individuals, like transplant and AIDS patients, are at high risk for developing severe CMV infections that can lead to a higher rate of morbidity and mortality. Roche’s COBAS® AmpliPrep/COBAS® TaqMan® CMV Test is used to monitor solid organ transplant patients for the risk of CMV disease development and the need for preemptive treatment, and for monitoring patients with active CMV disease for treatment response.
Roche is proud to provide products that safeguard blood and blood products, helping prevent infectious diseases from being transmitted through blood transfusions. Our state-of-the-art COBAS® TaqScreen® MPX test, which runs on the cobas s 201 platform, simultaneously detetcs HBV, HCV, HIV-1 and HIV-2.
The recently introduced cobas® 4800 platform provides easy-to-use test kits to detect sexually-transmitted infectious disease agents like C. trachomatis and N. gonorrhoeae (cobas® 4800 CT/NG Test). The cobas® HPV Test is a qualitative single tube multiplex assay that simultaneously detects 14 HPV high-risk genotypes but also identifies HPV Type 16 & 18 at clinically relevant levels.
In the intensive care field, our LightCycler® SeptiFast Test provides rapid and reliable detection and identification of 25 different pathogens which are responsible for 90% of all nosocomial systemic infections. The test is the first of its kind to use PCR technology and can detect and identify both bacterial and fungal sepsis pathogens in less than six hours.